BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33122197)

  • 1. PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
    Huang Z; Liu M; Li D; Tan Y; Zhang R; Xia Z; Wang P; Jiao B; Liu P; Ren R
    J Biol Chem; 2020 Dec; 295(52):18343-18354. PubMed ID: 33122197
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
    Front Immunol; 2022; 13():805311. PubMed ID: 35154122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein tyrosine phosphatase nonreceptor type 2 exerts antimetastatic functions in pancreatic ductal adenocarcinoma.
    Zhang S; Wang H; Mao P; Sun Q; Su H; Zhang Y; Shen S; Xu G; Wang L; Zou X; Zhan Q; Lv Y
    Mol Carcinog; 2023 Aug; 62(8):1176-1190. PubMed ID: 37204217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.
    Kasper SH; Spalinger MR; Raselli T; Scharl M
    Digestion; 2015; 91(3):248-56. PubMed ID: 25823847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells.
    Assi M; Achouri Y; Loriot A; Dauguet N; Dahou H; Baldan J; Libert M; Fain JS; Guerra C; Bouwens L; Barbacid M; Lemaigre FP; Jacquemin P
    Cancer Res; 2021 May; 81(10):2679-2689. PubMed ID: 33602788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
    Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
    Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.
    Scharl M; Mwinyi J; Fischbeck A; Leucht K; Eloranta JJ; Arikkat J; Pesch T; Kellermeier S; Mair A; Kullak-Ublick GA; Truninger K; Noreen F; Regula J; Gaj P; Pittet V; Mueller C; Hofmann C; Fried M; McCole DF; Rogler G
    Inflamm Bowel Dis; 2012 May; 18(5):900-12. PubMed ID: 22021207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic β-cell apoptosis via regulation of the BH3-only protein Bim.
    Santin I; Moore F; Colli ML; Gurzov EN; Marselli L; Marchetti P; Eizirik DL
    Diabetes; 2011 Dec; 60(12):3279-88. PubMed ID: 21984578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer.
    Jeung HC; Puentes R; Aleshin A; Indarte M; Correa RG; Bankston LA; Layng FIAL; Ahmed Z; Wistuba I; Yao Y; Duenas DG; Zhang S; Meuillet EJ; Marassi F; Liddington RC; Kirkpatrick L; Powis G
    Exp Cell Res; 2021 Dec; 409(2):112930. PubMed ID: 34800542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
    Duval R; Bui LC; Mathieu C; Nian Q; Berthelet J; Xu X; Haddad I; Vinh J; Dupret JM; Busi F; Guidez F; Chomienne C; Rodrigues-Lima F
    J Biol Chem; 2019 Aug; 294(33):12483-12494. PubMed ID: 31248982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Ohm AM; Tan AC; Heasley LE; Reyland ME
    Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.